Quote | Aadi Bioscience Inc. (NASDAQ:AADI)
Last: | $2.05 |
---|---|
Change Percent: | 1.49% |
Open: | $2.06 |
Close: | $2.02 |
High: | $2.09 |
Low: | $2.02 |
Volume: | 43,400 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Aadi Bioscience Inc. (NASDAQ:AADI)
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precis...
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for h...
Message Board Posts | Aadi Bioscience Inc. (NASDAQ:AADI)
Subject | By | Source | When |
---|---|---|---|
$AADI: That megamove in$ RXDX today........ 36 to 100 | makinezmoney | investorshub | 12/07/2022 3:03:53 PM |
whytestocks: $AADI News Article - Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Co | whytestocks | investorshangout | 10/12/2022 12:40:48 PM |
$AADI: You saw $BMY buyout $TPTX today for $76/sh | makinezmoney | investorshub | 06/03/2022 2:44:55 PM |
whytestocks: $AADI News Article - Aadi Bioscience Reports First Quarter 2022 Financial Results and P | whytestocks | investorshangout | 05/12/2022 6:10:50 PM |
$AADI: With the Whacky way this trades............ | makinezmoney | investorshub | 11/24/2021 1:08:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Aadi Bioscience Inc. Company Name:
AADI Stock Symbol:
NASDAQ Market:
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precis...
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for h...
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) PR Newswire Subgroup experienced efficacy and safety consistent with overall study population ...